![Pierre Saint-Mezard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Nicholas Benedict | M | - |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
Damien Picard | M | - |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
Hedvika Lazar | F | - |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
Giovanni Mariggi | M | 39 |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
Rahul Ballal | M | 46 |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
Nick Williams | M | - |
Vaderis Therapeutics AG
![]() Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Svizzera | 6 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Pierre Saint-Mezard
- Contatti personali